Heights Capital Management
VC Fund
San Francisco, United States
Heights Capital Management is a VC fund in San Francisco focused on Biotechnology and Health Care. Heights Capital Management, Inc. is a private equity firm specializing in private investments in public equity in emerging growth companies. The firm typically invests in healthcare and technology companies. Heights Capital Management, Inc. was founded in 1996 and is based in San Francisco, California.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Heights Capital Management invests in
Stages Heights Capital Management invests in
Countries Heights Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 11 (33%)
- Health Care 8 (24%)
- Medical 6 (18%)
- Pharmaceutical 6 (18%)
- Therapeutics 5 (15%)
Stage
- Post-IPO Equity 13 (39%)
- Post-IPO Debt 5 (15%)
- Funding Round 4 (12%)
- Venture - Series Unknown 2 (6%)
- Series B 1 (3%)
Country
- United States 11 (33%)
- France 4 (12%)
- Japan 2 (6%)
- China 1 (3%)
- Canada 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Stephen Tam
Investor
|
Investor | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $2M / Post-IPO Equity / Mar 10, 2026 | |
|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $3.4M / Post-IPO Equity / Dec 26, 2025 | |
SEALSQ
|
SEALSQ is a provider of semiconductors that develops secure chips, embedded firmware, and trusted technology hardware and software products. | $200M / Post-IPO Equity / Oct 15, 2025 | |
IonQ
|
IONQ develops general-purpose quantum information processors to solve the world’s complex problems. Its unique trapped ion approach combines unmatched physical performance, perfect qubit replication, optical networkability, and highly optimized algorithms to create a quantum computer that is as scalable as it is powerful and that will support abroad array of applications across a variety of industries.It was founded in 2015 and is based in College Park, Maryland. | $2B / Post-IPO Equity / Oct 10, 2025 | |
|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $4.3M / Post-IPO Equity / Sep 26, 2025 | |
SynAct Pharma
|
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis.Preclinical studies show that AP1189 has aunique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected to be available during Q2 2018. The company intends to prepare for a first patient study in parallel with the completion of the phase I study. Assuming that AP1189 has proven safe and tolerable also in multiple dosing, the aim is to submit a clinical trial application (CTA) in patients with active arthritis (joint inflammation). After proof of concept has been shown in patients, the company intends to sign commercial agreements with one or more major pharmaceutical companies. | $1.8M / Post-IPO Equity / Jul 15, 2025 | |
|
SEALSQ
|
SEALSQ is a provider of semiconductors that develops secure chips, embedded firmware, and trusted technology hardware and software products. | $60M / Post-IPO Equity / Jul 14, 2025 | |
|
IonQ
|
IONQ develops general-purpose quantum information processors to solve the world’s complex problems. Its unique trapped ion approach combines unmatched physical performance, perfect qubit replication, optical networkability, and highly optimized algorithms to create a quantum computer that is as scalable as it is powerful and that will support abroad array of applications across a variety of industries.It was founded in 2015 and is based in College Park, Maryland. | $1B / Post-IPO Equity / Jul 07, 2025 | |
Crossject
|
Crossject specializes in manufacturing and marketing needleless drug self-injection. | $6.6M / Post-IPO Equity / Jun 24, 2025 | |
Faron Pharmaceuticals
|
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. | $16.6M / Post-IPO Debt / Apr 03, 2025 | |
| See all 33 investments → | |||
Co-Investors
Iroquois Capital
5 deals together
Invus
4 deals together
OrbiMed
4 deals together
Adage Capital Management
3 deals together
Ally Bridge Group
2 deals together
Alumni Capital Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Heights Capital Management invest in?
Heights Capital Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Post-IPO Debt stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Heights Capital Management?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Heights Capital Management?
The team at Heights Capital Management includes Stephen Tam (Investor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
